Welcome to our dedicated page for Inotiv SEC filings (Ticker: NOTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating toxicology tables, animal-welfare disclosures, and segment margins across Discovery and Safety Assessment versus Research Models can turn Inotiv’s SEC filings into a 300-page puzzle. If you have ever asked, “Where do I find Inotiv insider trading Form 4 transactions or the latest Inotiv quarterly earnings report 10-Q filing?” this page is built for you.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and S-4 the moment they post to EDGAR. Our platform extracts cash-flow swings, upcoming FDA audit risks, and contractual earn-out details, then serves plain-English dashboards. You will see Inotiv Form 4 insider transactions real-time, debt-covenant changes, and revenue by service line—all in one view. The same engine powers quick answers to the common search, “Inotiv SEC filings explained simply,” delivering side-by-side trend charts and an Inotiv earnings report filing analysis you can skim in minutes.
Need deeper dives? Use our AI summary links for understanding Inotiv SEC documents with AI, or jump straight to red-lined PDFs. Track an Inotiv executive stock transactions Form 4 alert before material announcements, open an Inotiv annual report 10-K simplified for five-year segment KPIs, review the Inotiv proxy statement executive compensation for pay-for-performance alignment, or scan an Inotiv 8-K material events explained digest after unexpected CRO contract wins. From real-time feeds to curated insights, every filing type is covered so you can focus on decisions, not document hunts.
Inotiv, Inc. (NOTV) announced that it has issued a press release with select preliminary unaudited financial results for its fourth quarter and fiscal year ended September 30, 2025. These early figures are being shared ahead of final audited results to give the market an initial view of the company’s recent performance.
The company also disclosed that President and CEO Robert Leasure, Jr. will present at the Jefferies Global Healthcare Conference on November 18, 2025 at 6:00 a.m. Eastern time. A live webcast and replay of this presentation will be available through the Investors section of Inotiv’s website. The press release containing the preliminary results is furnished as Exhibit 99.1.
Inotiv (NOTV): Director Form 4 filing — Director R. Matthew Neff reported selling 2,000 shares of common stock on
Inotiv, Inc. (NOTV) reported an insider transaction. Director R. Matthew Neff exercised a stock option and acquired 10,000 shares of common stock at $1.94 per share on 10/24/2025 (Transaction Code M). Following the transaction, he directly beneficially owns 155,102 common shares. The exercised derivative was a director stock option covering 10,000 underlying shares, which now has 0 remaining after the exercise; the option carried an expiration date of 10/27/2025.
R. Matthew Neff, a director of Inotiv, Inc. (Ticker: NOTV), reported the sale of 2,000 shares of common stock on 10/01/2025 at a weighted average price of $1.4289 per share. The filing shows 145,102 shares remain beneficially owned by Mr. Neff after the reported sale.
The filing states the sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on February 13, 2025, and that the reported price is the weighted average of multiple sales that ranged from $1.4100 to $1.4650 per share. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Neff.
Inotiv, Inc. (NOTV) director R. Matthew Neff sold 2,000 shares of common stock on 09/02/2025 under a pre-established Rule 10b5-1 trading plan. The reported weighted average sale price was $1.6688 per share, with individual sale prices ranging from $1.6550 to $1.6900. After the transactions, Neff beneficially owns 147,102 shares. The Form 4 was signed by Beth Taylor as attorney-in-fact on 09/04/2025 and includes an undertaking to provide per-price sale detail to regulators or holders upon request.
Inotiv, Inc. (NOTV) Form 144 reports a proposed sale of 6,000 common shares through The Charles Schwab Corporation with an aggregate market value of $10,000. The filing lists 34,354,251 shares outstanding and an approximate sale date of 09/02/2025. The shares were acquired as restricted stock that vested on 04/01/2023. The filing also discloses prior sales by the same person of 2,000 shares on 07/01/2025 (gross proceeds $3,620) and 2,000 shares on 08/01/2025 (gross proceeds $3,818). The signer represents they have no undisclosed material nonpublic information.
Inotiv, Inc. (NASDAQ: NOTV) is filing an S-3 shelf prospectus to permit future offerings of securities, including an at-the-market equity program managed by Jefferies. The company describes two operating segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS), which together provide nonclinical drug development services and research animals/products to pharmaceutical, device, academic and government clients. The prospectus states net proceeds are expected to be used for working capital and general corporate purposes, and sales may occur from time to time at varying prices under a sales agreement with Jefferies that pays up to 3.0% commission. The registrant discloses an auditor’s report from Ernst & Young LLP that includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern and notes material weaknesses in internal control over financial reporting. The filing warns investors of immediate dilution risk, variability of proceeds from ATM sales, and typical forward-looking statement cautions.
FAQ
What is the current stock price of Inotiv (NOTV)?
What is the market cap of Inotiv (NOTV)?
